Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK | PLOS ONE
![PDF] Salting-Out Assisted Liquid-Liquid Extraction for Quantification of Febuxostat in Plasma Using RP-HPLC and Its Pharmacokinetic Application. | Semantic Scholar PDF] Salting-Out Assisted Liquid-Liquid Extraction for Quantification of Febuxostat in Plasma Using RP-HPLC and Its Pharmacokinetic Application. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/33e5db4338c422309c2071a048dd75ce56a8e02e/2-Figure1-1.png)
PDF] Salting-Out Assisted Liquid-Liquid Extraction for Quantification of Febuxostat in Plasma Using RP-HPLC and Its Pharmacokinetic Application. | Semantic Scholar
![FAST study finds no increased risk of cardiovascular events with febuxostat as compared with allopurinol for gout FAST study finds no increased risk of cardiovascular events with febuxostat as compared with allopurinol for gout](https://scx2.b-cdn.net/gfx/news/hires/2014/gout.png)